The HDDC3 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the HDDC3 gene in a human lung adenocarcinoma model. Unlike monoclonal knockout lines, this polyclonal format provides a heterogeneous pool of edited cells, minimizing clonal selection artifacts and offering a more physiologically relevant platform for functional genomics studies. Researchers can leverage this model to investigate HDDC3-dependent phenotypes without the confounding effects of single-cell-derived genotypic or phenotypic drift.
The parental NCI-H1975 cell line is derived from a non-small cell lung cancer patient and harbors an activating EGFR L858R point mutation in the tyrosine kinase domain. This mutation drives constitutive downstream signaling through pathways including RAS-MAPK and PI3K-AKT, contributing to proliferation and survival. NCI-H1975 cells are extensively used to study EGFR-targeted therapy resistance, tumor metabolism, and the biology of lung adenocarcinoma, making them an ideal host for interrogating HDDC3 function in an oncogenic background.
HDDC3 encodes a bifunctional enzyme that hydrolyzes ppGpp and NADPH. Its activity is stimulated by nutrient deprivation and mTORC1 inactivation, leading to ppGpp clearance and autophagy induction via the ULK1 kinase complex. Concurrent NADPH depletion impairs GPX4-mediated lipid peroxide reduction, promoting ferroptosis. Thus, HDDC3 funnels metabolic stress signals through mTOR to regulate both autophagic and ferroptotic programs. Representative pathway constituents include mTOR, ULK1, BECN1, LC3, p62, ppGpp, NADPH, GPX4, and ACSL4.
In NCI-H1975 cells harboring EGFR L858R, HDDC3 knockout is critical for examining how oncogenic signaling affects metabolic stress adaptation. These lung adenocarcinoma cells frequently rely on autophagy and ferroptosis evasion for survival under nutrient-poor conditions; HDDC3 loss can disrupt these protective mechanisms, potentially unveiling therapeutic susceptibilities. This model facilitates quantitative analysis of autophagy flux, ferroptosis induction, and cell viability upon metabolic challenge or drug treatment, linking HDDC3 function to NSCLC pathology.
The polyclonal knockout cells are amenable to diverse assays: immunoblotting for HDDC3, LC3, and p62; immunofluorescence detection of LC3 puncta; and RT-qPCR validation of HDDC3 disruption. Ferroptosis studies benefit from lipid ROS measurement with C11-BODIPY, GPX4 expression analysis, and viability assays using erastin or RSL3. Applications extend to metabolic profiling and drug resistance screening. For technical support, contact Ascent Research.
